Subthalamic nucleus deep brain stimulation for Parkinson's disease: current trends and future directions.

Deep brain stimulation lead technology neuroimaging neuroimaging side effects neurophysiology side effects subthalamic nucleus

Journal

Expert review of medical devices
ISSN: 1745-2422
Titre abrégé: Expert Rev Med Devices
Pays: England
ID NLM: 101230445

Informations de publication

Date de publication:
Oct 2020
Historique:
pubmed: 7 4 2020
medline: 18 12 2020
entrez: 7 4 2020
Statut: ppublish

Résumé

Over the last three decades, extensive basic and clinical research has been performed on the use of subthalamic nucleus (STN) as the preferred deep brain stimulation (DBS) target for the treatment of Parkinson's disease (PD). The mechanism underlying the benefit for the motor symptoms in PD is related to the modulation of firing patterns within the hyperdirect projections from motor cortical areas, as well as within the afferent and efferent fibers to the motor STN. Advancements in neuroimaging techniques allow us to identify precisely the STN optimizing surgical targeting. In this review, we provide an update on the current uses of STN-DBS as a routine therapy as well as its experimental indications in PD, the critical aspects associated with its successful implementation and recent advances in DBS technology.

Identifiants

pubmed: 32250645
doi: 10.1080/17434440.2020.1747433
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1063-1074

Auteurs

Antonella Macerollo (A)

Department of Neurology, The Walton Centre NHS Foundation Trust , Liverpool, UK.
School of Psychology, Faculty of Health and Life Sciences, University of Liverpool , Liverpool, UK.
Unit of Functional Neurosurgery, National Hospital for Neurology and Neurosurgery , London, UK.

Ludvic Zrinzo (L)

Unit of Functional Neurosurgery, National Hospital for Neurology and Neurosurgery , London, UK.
Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology , London, UK.

Harith Akram (H)

Unit of Functional Neurosurgery, National Hospital for Neurology and Neurosurgery , London, UK.
Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology , London, UK.

Thomas Foltynie (T)

Unit of Functional Neurosurgery, National Hospital for Neurology and Neurosurgery , London, UK.
Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology , London, UK.

Patricia Limousin (P)

Unit of Functional Neurosurgery, National Hospital for Neurology and Neurosurgery , London, UK.
Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology , London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH